Page 107 - 中国全科医学2022-15

·1896· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

mellitus and cardiovascular disease［J］. Curr Cardiol Rep，2019， 52 week results from a randomised，double-blind，phase 3 non-
21（4）：21. DOI：10.1007/s11886-019-1107-y. inferiority trial［J］. Lancet，2013，382（9896）：941-950.
［2］KAUSHAL S，SINGH H，THANGARAJU P，et al. Canagliflozin： DOI：10.1016/S0140-6736（13）60683-2.
a novel SGLT2 inhibitor for type 2 diabetes mellitus［J］. N Am ［14］LAVALLE-GONZÁLEZ F J，JANUSZEWICZ A，DAVIDSON J，
J Med Sci，2014，6（3）：107-113. DOI：10.4103/1947- et al. Efficacy and safety of canagliflozin compared with placebo and
2714.128471. sitagliptin in patients with type 2 diabetes on background metformin
［3］ELKINSON S，SCOTT L J. Canagliflozin：first global approval［J］. monotherapy：a randomised trial［J］. Diabetologia，2013，56（12）：
Drugs，2013，73（9）：979-988. DOI：10.1007/s40265-013- 2582-2592. DOI：10.1007/s00125-013-3039-1.
0064-9. ［15］JI L，HAN P，LIU Y，et al. Canagliflozin in Asian patients with
［4］LAMOS E M，YOUNK L M，DAVIS S N. Canagliflozin，an type 2 diabetes on metformin alone or metformin in combination with
inhibitor of sodium-glucose cotransporter 2，for the treatment of type sulphonylurea［J］. Diabetes Obes Metab，2015，17（1）：23-
2 diabetes mellitus［J］. Expert Opin Drug Metab Toxicol，2013，9 31. DOI：10.1111/dom.12385.
（6）：763-775. DOI：10.1517/17425255.2013.791282. ［16］FORST T，GUTHRIE R，GOLDENBERG R，et al. Efficacy and
［5］ZILOV A V，ABDELAZIZ S I，ALSHAMMARY A，et al. safety of canagliflozin over 52 weeks in patients with type 2 diabetes
Mechanisms of action of metformin with special reference to on background metformin and pioglitazone［J］. Diabetes Obes
cardiovascular protection［J］. Diabetes Metab Res Rev，2019，35 Metab，2014，16（5）：467-477. DOI：10.1111/dom.12273.
（7）：e3173. DOI：10.1002/dmrr.3173. ［17］YANG T，LU M，MA L Y，et al. Efficacy and tolerability of
［6］Expert Committee on the Diagnosis and Classification of Diabetes canagliflozin as add-on to metformin in the treatment of type 2
Mellitus. Report of the expert committee on the diagnosis and diabetes mellitus：a meta-analysis［J］. Eur J Clin Pharmacol，
classification of diabetes mellitus［J］. Diabetes Care，2003，26（Suppl 2015，71（11）：1325-1332. DOI：10.1007/s00228-015-
1）：S5-20. DOI：10.2337/diacare.26.2007.s5. 1923-y.
［7］HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. The ［18］GONZALEZ D E，FORESTO R D，RIBEIRO A B. SGLT-2
Cochrane Collaboration's tool for assessing risk of bias in randomised inhibitors in diabetes：a focus on renoprotection［J］. Rev Assoc
trials［J］. BMJ，2011，343：d5928. DOI：10.1136/bmj.d5928. Med Bras （1992），2020，66 Suppl（Suppl 1）：s17-24.
［8］WILDING J P，CHARPENTIER G，HOLLANDER P，et al. DOI：10.1590/1806-9282.66.S1.17.
Efficacy and safety of canagliflozin in patients with type 2 diabetes ［19］HUMMEL C S，LU C，LOO D D，et al. Glucose transport by
mellitus inadequately controlled with metformin and sulphonylurea： human renal Na+/D-glucose cotransporters SGLT1 and SGLT2［J］.
a randomised trial［J］. Int J Clin Pract，2013，67（12）：1267- Am J Physiol Cell Physiol，2011，300（1）：C14-21. DOI：
1282. DOI：10.1111/ijcp.12322. 10.1152/ajpcell.00388.2010.
［9］SCHERNTHANER G，GROSS J L，ROSENSTOCK J，et al. ［20］FERRANNINI E，MUSCELLI E，FRASCERRA S，et al.
Canagliflozin compared with sitagliptin for patients with type 2 Metabolic response to sodium-glucose cotransporter 2 inhibition in
diabetes who do not have adequate glycemic control with metformin type 2 diabetic patients［J］. J Clin Invest，2014，124（2）：
plus sulfonylurea：a 52-week randomized trial［J］. Diabetes 499-508. DOI：10.1172/JCI72227.
Care，2013，36（9）：2508-2515. DOI：10.2337/dc12-2491. ［21］MARTINEZ R，AL-JOBORI H，ALI A M，et al. Endogenous
［10］ROSENSTOCK J，CHUCK L，GONZÁLEZ-ORTIZ M，et al. glucose production and hormonal changes in response to canagliflozin
Initial combination therapy with canagliflozin plus metformin and liraglutide combination therapy［J］. Diabetes，2018，67（6）：
versus each component as monotherapy for drug-naïve type 2 1182-1189. DOI：10.2337/db17-1278.
diabetes［J］. Diabetes Care，2016，39（3）：353-362. DOI： ［22］NESCHEN S，SCHEERER M，SEELIG A，et al. Metformin
10.2337/dc15-1736. supports the antidiabetic effect of a sodium glucose cotransporter 2
［11］ROSENSTOCK J，AGGARWAL N，POLIDORI D，et al. Dose- inhibitor by suppressing endogenous glucose production in diabetic
ranging effects of canagliflozin，a sodium-glucose cotransporter mice［J］. Diabetes，2015，64（1）：284-290. DOI：10.2337/
2 inhibitor，as add-on to metformin in subjects with type 2 db14-0393.
diabetes［J］. Diabetes Care，2012，35（6）：1232-1238. ［23］ROSENT H AL N，MEININGER G，W AYS K，et al.
DOI：10.2337/dc11-1926. Canagliflozin：a sodium glucose co-transporter 2 inhibitor for the
［12］QIU R，CAPUANO G，MEININGER G. Efficacy and safety of treatment of type 2 diabetes mellitus［J］. Ann N Y Acad Sci，
twice-daily treatment with canagliflozin，a sodium glucose co- 2015，1358：28-43. DOI：10.1111/nyas.12852.
transporter 2 inhibitor，added on to metformin monotherapy ［24］T AKASHIMA H，YOSHIDA Y，NAGURA C，et al.
in patients with type 2 diabetes mellitus［J］. J Clin Transl Renoprotective effects of canagliflozin，a sodium glucose
Endocrinol，2014，1（2）：54-60. DOI：10.1016/j. cotransporter 2 inhibitor，in type 2 diabetes patients with chronic
jcte.2014.04.001. kidney disease：a randomized open-label prospective trial［J］.
［13］CEFALU W T，LEITER L A，YOON K H，et al. Efficacy and Diab Vasc Dis Res，2018，15（5）：469-472. DOI：
safety of canagliflozin versus glimepiride in patients with type 2 10.1177/1479164118782872.
diabetes inadequately controlled with metformin （CANTATA-SU）： （下转第1905页）